Valuation: VACY AS

Market Cap 1.03B 0 104M 91.07M 83.63M 77.99M 148M 9.92B 150M 1.01B 390M 4.87B 391M 383M 16.77B P/E 2026 *
-4.86x
P/E 2027 * -33.9x
Enterprise Value 540M 0 54.92M 47.99M 44.06M 41.09M 77.9M 5.23B 79.22M 531M 206M 2.56B 206M 202M 8.84B EV / Sales 2026 *
-
EV / Sales 2027 * 2.77x
Free-Float
56.4%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 54 01/01/2019
President 49 01/01/2017
Director of Finance/CFO 51 03/05/2021
Director TitleAgeSince
Director/Board Member 54 -
Director/Board Member 57 -
Chairman 45 23/04/2025
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 104M
-0.82%+4.28%+77.67%+134.12% 58.73B
-3.12%+3.48%+72.79%+94.67% 53.92B
+3.86%+8.38%-9.90%-9.62% 24.67B
+4.30%+6.82%+13.60%+428.91% 24.19B
+4.74%+13.68%+45.58%-1.42% 18.8B
-0.99%+8.90%+43.46%-28.52% 17.61B
+2.57%+16.74%+171.12%+355.99% 16.25B
+3.50%+4.92%+26.07%+192.26% 14.04B
+6.72%+19.38%+42.82% - 13.9B
Average +2.07%+8.85%+53.69%+145.80% 26.9B
Weighted average by Cap. +0.97%+7.21%+57.56%+136.17%

Financials

2026 *2027 *
Net sales - 162M 0 16.44M 14.36M 13.19M 12.3M 23.32M 1.56B 23.71M 159M 61.54M 768M 61.72M 60.38M 2.64B
Net income -208M -0 -21.13M -18.47M -16.96M -15.81M -29.98M -2.01B -30.48M -204M -79.12M -987M -79.35M -77.63M -3.4B -41.58M -0 -4.23M -3.69M -3.39M -3.16M -6M -402M -6.1M -40.83M -15.83M -197M -15.87M -15.53M -680M
Net Debt -485M -0 -49.31M -43.09M -39.57M -36.9M -69.95M -4.69B -71.13M -476M -185M -2.3B -185M -181M -7.93B -578M -0 -58.7M -51.3M -47.1M -43.93M -83.27M -5.59B -84.68M -567M -220M -2.74B -220M -216M -9.45B
Logo VACY AS
Nykode Therapeutics ASA is a Norway-based clinical-stage biopharmaceutical platform company dedicated to the discovery and development of vaccines and immunotherapies for cancer and infectious diseases. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The Company develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The Company also has two universal COVID-19 vaccine candidates in development.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.140NOK
Average target price
5.000NOK
Spread / Average Target
+59.24%

Quarterly revenue - Rate of surprise